Evidence map›Paper›PMID 37984034›Full record

ArticleDrug and alcohol dependence2023

Utilization and disparities in medication treatment for opioid use disorder among patients with comorbid opioid use disorder and chronic pain during the COVID-19 pandemic.

Allison Perry, Katherine Wheeler-Martin, Deborah S Hasin, Kelly Terlizzi, Zachary L Mannes, Victoria Jent, Tarlise N Townsend, John R Pamplin, Stephen Crystal, Silvia S Martins and 2 more

Open access · greenAbstract read
In one paragraph

Article in Drug and alcohol dependence, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Allison PerryCenter for Opioid Epidemiology and Policy, Department of Population Health, NYU Grossman School of Medicine, New York, NY, United States. Electronic address: Allison.perry2@nyulangone.org.
Katherine Wheeler-MartinCenter for Opioid Epidemiology and Policy, Department of Population Health, NYU Grossman School of Medicine, New York, NY, United States.
Deborah S HasinDepartment of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, United States.
Kelly TerlizziDepartment of Population Health, NYU Grossman School of Medicine, New York, NY, United States.
Zachary L MannesDepartment of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, United States.
Victoria JentCenter for Opioid Epidemiology and Policy, Department of Population Health, NYU Grossman School of Medicine, New York, NY, United States.
Tarlise N TownsendCenter for Opioid Epidemiology and Policy, Department of Population Health, NYU Grossman School of Medicine, New York, NY, United States.
John R PamplinCenter for Opioid Epidemiology and Policy, Department of Population Health, NYU Grossman School of Medicine, New York, NY, United States; Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, United States.
Stephen CrystalRutgers Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, United States.
Silvia S MartinsDepartment of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, United States.
Magdalena CerdáCenter for Opioid Epidemiology and Policy, Department of Population Health, NYU Grossman School of Medicine, New York, NY, United States.
Noa KrawczykCenter for Opioid Epidemiology and Policy, Department of Population Health, NYU Grossman School of Medicine, New York, NY, United States.
New York University · USColumbia University · USRutgers, The State University of New Jersey · US

Funding

Substance Abuse Epidemiology Training Program (SAETP) at Columbia UniversityT32DA031099 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI DEBORAH S HASIN, Silvia Saboia Martins · 2012 to 2026
$6.1M
Examining the Synergistic Effects of Cannabis and Prescription Opioid Policies on Chronic Pain, Opioid Prescribing, and Opioid OverdoseR01DA045872 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CERDA, MAGDALENA, MARTINS, SILVIA SABOIA · 2019 to 2023
$4.3M
Opioid Overdoses among Medicaid Beneficiaries: Predictors, Outcomes, and State Policy EffectsR01DA047347 · NIDA · RUTGERS, THE STATE UNIV OF N.J. · PI CRYSTAL, STEPHEN · 2019 to 2022
$3.1M
Beyond Treatment Initiation: Enhancing Opioid Use Disorder Care Transitions Across Health System TouchpointsK01DA055758 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Noa Krawczyk · 2023 to 2026
$722k
Barriers to and Health Consequences of Non- Pharmacological Chronic Pain Treatment among Patients Tapering Prescription Opioids in a Large Integrated Healthcare SystemK01AT012205 · NCCIH · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Zachary L Mannes · 2023 to 2026
$532k
NCCIH NIH HHS K01 AT012205NIDA NIH HHS K01 DA055758NIDA NIH HHS R01 DA045872NIDA NIH HHS R01 DA047347NIDA NIH HHS T32 DA031099
6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic's impact on utilization of medications for opioid use disorder (MOUD) among patients with opioid use disorder (OUD) and chronic pain is unclear.

methodsWe analyzed New York State (NYS) Medicaid claims from pre-pandemic (August 2019-February 2020) and pandemic (March 2020-December 2020) periods for beneficiaries with and without chronic pain. We calculated monthly proportions of patients with OUD diagnoses in 6-month-lookback windows utilizing MOUD and proportions of treatment-naïve patients initiating MOUD. We used interrupted time series to assess changes in MOUD utilization and initiation rates by medication type and by race/ethnicity.

resultsAmong 20,785 patients with OUD and chronic pain, 49.3% utilized MOUD (versus 60.3% without chronic pain). The pandemic did not affect utilization in either group but briefly disrupted initiation among patients with chronic pain (β=-0.009; 95% CI [-0.015, -0.002]). Overall MOUD utilization was not affected by the pandemic for any race/ethnicity but opioid treatment program (OTP) utilization was briefly disrupted for non-Hispanic Black individuals (β=-0.007 [-0.013, -0.001]). The pandemic disrupted overall MOUD initiation in non-Hispanic Black (β=-0.007 [-0.012, -0.002]) and Hispanic individuals (β=-0.010 [-0.019, -0.001]).

conclusionsAdults with chronic pain who were enrolled in NYS Medicaid before the COVID-19 pandemic had lower MOUD utilization than those without chronic pain. MOUD initiation was briefly disrupted, with disparities especially in racial/ethnic minority groups. Flexible MOUD policy initiatives may have maintained overall treatment utilization, but disparities in initiation and care continuity remain for patients with chronic pain, and particularly for racial/ethnic minoritized subgroups.

Indexed as

BuprenorphineChronic PainCOVID-19Opioid-Related DisordersAdultAnalgesics, OpioidEthnicityHumansMinority GroupsOpiate Substitution TreatmentPandemicsUnited StatesAnalgesics, OpioidBuprenorphineChronic painCOVID-19 pandemicMedicaidOpioid use disorder (OUD)

Identifiers

PMID37984034
PMCPMC10841620
OpenAlexW4388591469

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.